A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia

Authors:	Rupa Narayan MD Traci M Blonquist MS Ashkan Emadi MD PhD Robert P Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S Neuberg ScD Andrew M Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A Graubert MD Christina Bertoli MSN Jenna A Moran MSN Meghan K Bergeron MSN Julia E Foster MSN Aura Y Ramos BSN Tina T Som BSN Megan K Vartanian BSN RN Jennifer L Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C Wey PhD Jessica Rae BSN Frederic I Preffer PhD Patricia Lesho BA Vu H Duong MD Mason L Mann BA Karen K Ballen MD Christine Connolly BS Philip C Amrein MD Amir T Fathi MD

Affiliation:	1. Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts;2. Division of Biostatistics, Dana-Farber Cancer Institute, Boston, Massachusetts;3. Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Abstract:

Keywords:	acute myeloid leukemia antibody-drug conjugate brentuximab vedotin CD30 cytarabine etoposide immunoconjugate Ki-1 antigen mitoxantrone refractory relapsed